Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emma L Turner

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Specificity of a polygenic score for aggressive prostate cancerAnna M Dornisch, George J Xu, Roshan Karunamuni, et al.
European Urology|July 7, 2020
Erratum to 'Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received' [European Urology 77 (2020) 320-330]David E Neal, Chris Metcalfe, Jenny L Donovan, et al.
JAMA|March 7, 2018
Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical TrialRichard M Martin, Jenny L Donovan, Emma L Turner, et al.
European Urology|November 28, 2019
Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment ReceivedDavid E Neal, Chris Metcalfe, Jenny L Donovan, et al.
BJU International|April 4, 2022
Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study)Janet Athene Lane, Jenny L Donovan, Grace J Young, et al.
The New England Journal of Medicine|March 13, 2023
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate CancerFreddie C Hamdy, Jenny L Donovan, J Athene Lane, et al.
British Journal of Cancer|June 3, 2016
Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committeeEmma L Turner, Chris Metcalfe, Jenny L Donovan, et al.
Health Technology Assessment (Winchester, England)|August 11, 2020
Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCTFreddie C Hamdy, Jenny L Donovan, J Athene Lane, et al.
NEJM Evidence|February 6, 2024
Patient-Reported Outcomes 12 Years after Localized Prostate Cancer TreatmentJenny L Donovan, Freddie C Hamdy, J Athene Lane, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 26, 2020
A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population DataMinh-Phuong Huynh-Le, Chun Chieh Fan, Roshan Karunamuni, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Specificity of a polygenic score for aggressive prostate cancerAnna M Dornisch, George J Xu, Roshan Karunamuni, et al.
European Urology|July 7, 2020
Erratum to 'Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received' [European Urology 77 (2020) 320-330]David E Neal, Chris Metcalfe, Jenny L Donovan, et al.
JAMA|March 7, 2018
Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical TrialRichard M Martin, Jenny L Donovan, Emma L Turner, et al.
European Urology|November 28, 2019
Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment ReceivedDavid E Neal, Chris Metcalfe, Jenny L Donovan, et al.
BJU International|April 4, 2022
Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study)Janet Athene Lane, Jenny L Donovan, Grace J Young, et al.
The New England Journal of Medicine|March 13, 2023
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate CancerFreddie C Hamdy, Jenny L Donovan, J Athene Lane, et al.
British Journal of Cancer|June 3, 2016
Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committeeEmma L Turner, Chris Metcalfe, Jenny L Donovan, et al.
Health Technology Assessment (Winchester, England)|August 11, 2020
Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCTFreddie C Hamdy, Jenny L Donovan, J Athene Lane, et al.
NEJM Evidence|February 6, 2024
Patient-Reported Outcomes 12 Years after Localized Prostate Cancer TreatmentJenny L Donovan, Freddie C Hamdy, J Athene Lane, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 26, 2020
A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population DataMinh-Phuong Huynh-Le, Chun Chieh Fan, Roshan Karunamuni, et al.
Pageof 5